Moderna’s Suit Against Pfizer/BioNTech Is About More Than Money
Moderna is seeking financial compensation for Comirnaty in its patent infringement suit, but it seems especially keen to assert IP rights over what could become an even more valuable platform technology.
You may also be interested in...
Pfizer Strengthens Foundation For A Long-Term COVID Commercial Business
Preparing for the eventual transition to an open commercial market for COVID-19 vaccines and treatments, Pfizer restructured its commercial team to incorporate the franchises.
New Patent Battles Emerge Over What Lipid Technology Is Used In mRNA COVID-19 Vaccines
Alnylam seeks royalties, claiming its lipid nanoparticle technology is a component of both Moderna’s and Pfizer’s vaccines. Moderna calls Alnylam’s suit ‘blatant opportunism.’ Acuitas sues Arbutus seeking declaratory judgement that Comirnaty does not infringe its LPN technology.
Gilead’s Kite Hopes To Reinforce Commercial CAR-T Lead With Yescarta Data
The company presented results from the ZUMA-7 trial at ASCO for the CAR-T therapy in the curative setting of large B-cell lymphoma.